Open AccessPreimplantation genetic diagnosis: an update on current technologies and ethical considerations
Author(s) -
Sueoka Kou
Publication year - 2016
Publication title -
reproductive medicine and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.005
H-Index - 22
eISSN - 1447-0578
pISSN - 1445-5781
DOI - 10.1007/s12522-015-0224-6
Subject(s) - preimplantation genetic diagnosis , reproductive medicine , genetic testing , genetic engineering , ethical issues , assisted reproductive technology , genetic diagnosis , engineering ethics , emerging technologies , medicine , biology , computational biology , risk analysis (engineering) , embryo , genetics , computer science , engineering , pregnancy , gene , infertility , artificial intelligence
The aim of reproductive medicine is to support the birth of healthy children. Advances in assisted reproductive technologies and genetic analysis have led to the introduction of preimplantation genetic diagnosis (PGD) for embryos. Indications for PGD have been a major topic in the fields of ethics and law. Concerns vary by nation, religion, population, and segment, and the continued rapid development of new technologies. In contrast to the ethical augment, technology has been developing at an excessively rapid speed. The most significant recent technological development provides the ability to perform whole genome amplification and sequencing of single embryonic cells by microarray or next‐generation sequencing methods. As new affordable technologies are introduced, patients are presented with a growing variety of PGD options. Simultaneously, the ethical guidelines for the indications for testing and handling of genetic information must also rapidly correspond to the changes.